Skip to Main Content

Paper Details

<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
Medicina (Kaunas)
6
2022
BC, ER, HGSOC, OC, PARP, Patients, Platinum, Poly ADP-Ribose, Poly ADP-Ribose Polymerase, RNA, Tumors, bladder cancer, breast cancer, cancer of unknown, cervical cancer, cholangiocarcinoma, endometrial cancer, high-grade serous ovarian cancers, malignant pleural mesothelioma, neuroendocrine tumor of the prostate, ovarian cancer, pancreatic cancer, patients, platinum, prostate cancer, reading frame, tumor
Author NameAffiliation
Joanne Xiu
Emmanuel S AntonarakisUniversity of Minnesota Masonic Cancer Center
David Spetzler
Michael J DemeureHoag Family Cancer Institute
Michael J DemeureTranslational Genomics Research Institute
  • 1 - 5

Datasets

Release 1.2